Evolving and expanding treatment options in NSCLC.
作者信息
Knoop Teresa
出版信息
Oncology (Williston Park). 2012 Aug;26(8 Suppl Nurse Ed):13-4.
PMID:25375004
Abstract
摘要
相似文献
1
Evolving and expanding treatment options in NSCLC.
Oncology (Williston Park). 2012 Aug;26(8 Suppl Nurse Ed):13-4.
2
Contemporary issues in NSCLC.
Oncology (Williston Park). 2012 Aug;26(8 Suppl Nurse Ed):14-5.
3
Precision Medicine in Non-Small Cell Lung Cancer: Current Standards in Pathology and Biomarker Interpretation.
Am Soc Clin Oncol Educ Book. 2018 May 23;38:708-715. doi: 10.1200/EDBK_209089.
4
Artificial Intelligence Enhances NSCLC Care by Predicting Treatment Outcomes, Validating Neoadjuvant Therapies, and Improving Precision.
J Thorac Oncol. 2024 May;19(5):666-667. doi: 10.1016/j.jtho.2024.02.003.
5
Review of treatment options for oligometastatic non-small cell lung cancer.
Clin Adv Hematol Oncol. 2015 Mar;13(3):186-93.
6
The biology and management of non-small cell lung cancer.
Nature. 2018 Jan 24;553(7689):446-454. doi: 10.1038/nature25183.
7
Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients.
Lung Cancer. 2017 May;107:100-107. doi: 10.1016/j.lungcan.2016.04.026. Epub 2016 May 4.
8
Evolving Treatment Options for Lung Cancer.
Hematol Oncol Clin North Am. 2017 Feb;31(1):xiii-xiv. doi: 10.1016/j.hoc.2016.09.001.
9
The role of cytology in molecular testing and personalized medicine in lung cancer: A clinical perspective.
Cancer Cytopathol. 2019 Feb;127(2):72-78. doi: 10.1002/cncy.22085. Epub 2018 Dec 4.
10
Editorial: Individualizing treatment of nonsmall cell lung cancer.
Curr Opin Oncol. 2020 Jan;32(1):35-36. doi: 10.1097/CCO.0000000000000597.
Zotero 插件